Evolus
Newport Beach, California, United States · Fitness, Healthcare, Health Care
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technol
Key facts
- Headquarters
- Newport Beach, California, United States
- Employees
- 400
- Industries
- Fitness, Healthcare, Health Care
- Status
- Public (EOLS)
- Website
- evolus.com
- Company page
Recent activity at Evolus
- : Evolus Expands Partnership with Symatese to Commercialize HA Gels in Canada, Australia, and New Zealand.
- : SEC 8-K (1.01): On August 3, 2026, Evolus Pharma B.V., a subsidiary of Evolus, Inc., entered into a material amendment to their existing License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. This amendment expands the agreement to include exclusive rights for Evolus Europe to commercialize and distribute Estyme® branded injectable hyaluronic acid gels in Canada, Australia, and New Zealand. As part of the amendment, Evolus Europe will pay €920,000 upfront and potentially an additional €1.38 million upon obtaining certain regulatory approvals. The amendment also stipulates an initial term of 15 years for the new territories, which will automatically renew for successive five-year terms, subject to the agreement's conditions.
- : SEC 8-K (1.01): On July 7, 2026, Evolus, Inc. and IBSA Institut Biochimique SA entered into a License, Supply, and Distribution Agreement which grants Evolus exclusive rights to develop, commercialize, and distribute Profhilo®, an injectable hyaluronic acid product, in the United States. Evolus is responsible for the FDA approval process and will purchase the product under a transfer-price model once approved. The initial term of the agreement is fifteen years, with potential renewal options, and includes minimum purchase requirements after the fourth year that could affect the exclusivity of rights. The agreement does not include upfront or milestone payments.
- : SEC 8-K (5.07): On June 11, 2026, Evolus, Inc. conducted its Annual Meeting of Stockholders where the shareholders voted to elect Brady Stewart and Vikram Malik as Class II directors for a three-year term, concluding at the next Annual Meeting in 2029 or until their successors are elected. This election reflects significant governance changes within the company, ensuring the continuity of leadership. The results of the votes for these nominations were reported during the meeting, with clear outcomes indicating shareholder support for these candidates.
- : SEC 8-K (7.01): On May 1, 2026, the Company terminated its At-The-Market Sales Agreement with SVB Securities LLC, now known as Leerink Partners LLC, which had been in effect since March 8, 2023. This agreement allowed for the offer and sale of up to $50.0 million in shares of the Company's common stock. Notably, prior to its termination, the Company had not executed any sales under this agreement. The termination reflects a strategic decision by the Company regarding its capital-raising efforts and market approach, potentially impacting future funding opportunities.
- : Evolus Appoints Vikram Malik as Class II Director
- : SEC 8-K (5.02): On March 13, 2026, Evolus, Inc. reclassified Vikram Malik from Class III to Class II director to restore balance among the classes of directors after Simone Blank stepped down from the Board. Mr. Malik resigned from his Class III position immediately before being appointed as Class II director, ensuring his service remained continuous. He will serve until the 2026 annual meeting where Class II directors will stand for election, while continuing as Chairman of the Board and a member of the Compensation Committee. His existing equity awards will continue to vest as per original terms, and there are no new equity awards or conflicts requiring regulatory disclosure.
- : SEC 8-K (5.02): On March 13, 2026, Evolus, Inc. announced the reclassification of Vikram Malik from Class III to Class II of its board of directors following the resignation of Simone Blank. This reclassification was necessary to maintain balance among the director classes after Ms. Blank stepped down to support board refreshment efforts. Mr. Malik's transition involved his immediate resignation as a Class III director, followed by his appointment as a Class II director. This strategic move is aimed at enhancing the diversity and effectiveness of the board's governance structure.
- : SEC 8-K (1.01): On March 3, 2026, Evolus, Inc. entered into a Loan and Security Agreement with Eclipse Business Capital LLC, which serves as the administrative agent. This agreement provides a senior secured asset-based revolving credit facility of up to $30 million, with an accordion feature of up to $10 million subject to certain conditions. The facility includes a minimum borrowing requirement of $10 million and has a maturity date of March 3, 2029. Borrowings incur interest linked to the adjusted term secured overnight financing rate with a floor of 2.0%, and various fees are applicable for closing and prepayments. Furthermore, this agreement imposes covenants that could affect the financial strategy and operational flexibility of Evolus.
- : SEC 8-K (1.01): On March 3, 2026, Evolus, Inc. entered into a Loan and Security Agreement with Eclipse Business Capital LLC. This agreement establishes a senior secured asset-based revolving credit facility amounting to up to $30 million, with an additional uncommitted accordion feature of $10 million. The facility is based on eligible accounts receivable and inventory, with a minimum utilization requirement of $10 million. The Loan Agreement matures on March 3, 2029, and includes terms for interest rates linked to standard adjustments.
Evolus funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2020 | Venture | $40.0M |
Leadership
- David Moatazedi, President and CEO
- Vikram Malik, Director
- Simone Blank, Director
- Peter Farrell, Director
- David Gill, Director
- Robert Hayman, Director
- Karah Parschauer, Director
- Tatjana Mitchell, Chief Financial Officer
- Albert G. White, President
- Nareg Sagherian, Vice President
Verified email and direct lines for Evolus’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Evolus files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Evolus in the news
- Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme - Business Wire (Aug 04, 2026)
- Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire (May 19, 2026)
- Evolus Submits Evolysse Sculpt for FDA Approval, Expanding HA Dermal Filler Portfolio - Dermatology Times (Aug 20, 2025)
- PrabotulinumtoxinA-xvfs (Jeuveau, Evolus) for the Temporary Treatment of Glabellar Lines: What Does This Toxin Bring to the Table? - The Dermatology Digest (Sep 10, 2025)
- Evolus leads with beauty, not pharma, in direct-to-millennial strategy for upstart Jeuveau - Fierce Pharma (Apr 08, 2020)
- A Rival to Botox Invites Doctors to Party in Cancun, With Fireworks, Confetti and Social Media Posts (Published 2019) - The New York Times (May 15, 2019)
- EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law - Business Wire (Oct 12, 2026)
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire (Jul 10, 2026)
Companies similar to Evolus
- Redi.Health · Fitness, Healthcare, Health Care, Wellness
- SMART FOR LIFE · Fitness, Healthcare, Health Care, Wellness
- Upgrade Labs · Fitness, Healthcare, Health Care, Wellness
- Whoop · Fitness, Healthcare, Health Care, Wellness
- Kickoff · Fitness, Health Care, Wellness
About Evolus: questions and answers
What does Evolus do?
Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technol
Where is Evolus headquartered?
Evolus is headquartered in Newport Beach, California, United States.
How many employees does Evolus have?
Evolus has about 400 employees.
Has Evolus raised funding?
Yes. Fundz has recorded 1 funding event for Evolus. The most recent, $40.0M, was in Jul 2020.
Who leads Evolus?
David Moatazedi is a President and CEO at Evolus.
What is the latest news on Evolus?
On Aug 04, 2026, Evolus Expands Partnership with Symatese to Commercialize HA Gels in Canada, Australia, and New Zealand.
Is Evolus a public company?
Yes. Evolus is publicly traded under the ticker EOLS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy